image credit: Unsplash

With FDA verging on its first COVID booster approval, Pfizer and Moderna will have to recalibrate revenues—again

August 12, 2021


Pfizer and Moderna are getting used to readjusting their projected COVID-19 vaccine sales. Now another recalibration may be in order.

The FDA is set to authorize a third dose of their COVID-19 shots for those with weakened immune systems, NBC News reports.

The agency’s decision for immunocompromised people, who do not mount an effective response to the currently authorized two-dose regimens from Pfizer and Moderna, could be a precursor to approvals for the elderly and then for other segments of the population to receive a third dose. For these individuals, the reason to vaccinate again would be because the protection they received from the first two doses may wane over time.

Read More on FiercePharma